Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Nipro Secures AG for Forxiga, Sawai and Teva Takeda Go Without Hydrate
Japan’s latest batch of generic approvals includes authorized generics (AGs) for at least one brand, Jiho has learned, with Nipro revealing that its versions of the SGLT2 inhibitor Forxiga (dapagliflozin propylene glycolate hydrate) are such licensed products. The Ministry of…
To read the full story
Related Article
- Nipro to List Forxiga AG in June Ahead of Pricing Rule Shift
April 30, 2026
- Forxiga Generics Launch in Japan at 33.6% of Originator Price: Sawai, T’s Pharma
December 5, 2025
- Vimpat Draws 10 Generic Entrants in December Listing; Forxiga Has Two, but Nipro AG Absent
December 4, 2025
- Sawai and T’s Pharma Won Forxiga Generics by Skirting Patent, Will the Strategy Hold?
September 11, 2025
- AGs Identified for 4 Brands in Latest Generic Approvals, Including Bonviva and Epadel
August 19, 2025
- Japan Approves First SGLT2 Generics, 12 Firms Pile into Vimpat Ahead of December Listing
August 18, 2025
REGULATORY
- Trazenta Draws 8 Generic Entrants as Japan Clears New DPP-4 Copies
August 17, 2026
- Stelara IV Biosimilar Can Be Used for Crohn’s Induction: MHLW
August 17, 2026
- PMDA Loses USB Containing Data on 286 People, 27 Companies
August 17, 2026
- MHLW Panel Finalizes Exemptions for OTC-Like Drug Charges
August 17, 2026
- Nakai Tapped as MHLW’s Top Pharmacy Officer; Ohara to Steer Drug Pricing Reform
August 7, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…